Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.47 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.47 |
| ▸ | ESR1 | P03372 | 1/20 | 0.46 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.46 |
| ▸ | PGR | P06401 | 1/20 | 0.46 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.46 |
| ▸ | AR | P10275 | 1/20 | 0.46 |
| ▸ | THRA | P10827 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | CTSB | P07858 | 1/20 | 0.46 |
| ▸ | CTSS | P25774 | 1/20 | 0.46 |
| ▸ | CTSK | P43235 | 1/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.45 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 2/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7111910 | 0.91 | CTSB (0.44) | FFAR1FFAR4ESR1NR3C1PGR | |
| SCHEMBL1559211 | 0.88 | CTSB (0.42) | L3MBTL1FFAR1FFAR4ESR1NR3C1 | |
| SCHEMBL1745431 | 0.86 | FFAR1 (0.70) | FFAR1FFAR4ESR1NR3C1PGR | |
| SCHEMBL11096512 | 0.85 | AKT1 (0.41) | L3MBTL1 | |
| SCHEMBL2909498 | 0.84 | MAOB (0.48) | CTSBCTSSCTSKRIPK1MAOB | |
| SCHEMBL13250326 | 0.83 | TDP1 (0.41) | L3MBTL1 | |
| SCHEMBL5262346 | 0.83 | SIRT2 (0.49) | — | |
| SCHEMBL7910720 | 0.83 | TDP1 (0.41) | L3MBTL1FFAR1 | |
| SCHEMBL28623133 | 0.83 | TDP1 (0.48) | L3MBTL1FFAR1FFAR4THRATHRB | |
| SCHEMBL2184610 | 0.83 | CTSB (0.42) | FFAR1FFAR4CTSBCTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024217537-A1 | TERTIARY AMINE COMPOUND AS WELL AS PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | 深圳信立泰药业股份有限公司 | 2024-10-24 | — | — | WO | disclosed |
| WO-2024026290-A1 | NOVEL HETEROCYCLES AS sPLA2-X INHIBITORS | CAYMAN CHEMICAL COMPANY INCORPORATED (US) | 2024-02-01 | — | — | WO | disclosed |
| US-9556160-B2 | Guanidine compound | ASTELLAS PHARMA INC. (JP) | 2017-01-31 | — | — | US | disclosed |
| US-20150203480-A1 | GUANIDINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2015-07-23 | — | — | US | disclosed |
| US-9051283-B2 | Guanidine compound | ASTELLAS PHARMA INC. (JP) | 2015-06-09 | — | — | US | disclosed |
| US-20130143860-A1 | GUANIDINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2013-06-06 | — | — | US | disclosed |
| EP-2441755-A1 | Pyridine- and isoquinoline-derivatives as Syk and JAK kinase inhibitors | Almirall, S.A. (ES) | 2012-04-18 | — | — | EP | disclosed |
| WO-2012041476-A1 | PYRIDINE AND ISOQUINOLINE DERIVATIVES AS SYK- AND JAK-KINASE INHIBITORS | ALMIRALL, S.A. (ES) | 2012-04-05 | — | — | WO | disclosed |
| EP-1013639-B1 | Aryl carboxylic acid and tetrazole derivatives comprising a carbamoyloxy unit | HOFFMANN LA ROCHE (CH) | 2003-10-01 | — | — | EP | disclosed |
| US-6335459-B1 | PROSTAGLANDIN I2 RECEPTOR MODULATORS; TREATING TISSUE NECROSIS, PREMATURE UTERINE CONTRACTION, GASTRIC ULCERATION, SEXUAL DYSFUNCTION, MENSTRUAL PAIN AND IMPROPER WOUND HEALING, IMMUNOREGULATION, PLATELET AGGREGATION OR NEUTROPHIL FUNCTION | SYNTEX (U.S.A.) LLC | 2002-01-01 | — | — | US | disclosed |
| EP-1013639-A1 | Aryl carboxylic acid and tetrazole derivatives comprising a carbamoyloxy unit | F. HOFFMANN-LA ROCHE AG (CH) | 2000-06-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130143860-A1 | GUANIDINE COMPOUND | GUCY1A1, VAPA, VAPB | L3MBTL1 2495/4885FFAR1 2212/4885FFAR4 3672/4885 |
| US-20150203480-A1 | GUANIDINE COMPOUND | GUCY1A1, VAPA, VAPB | L3MBTL1 2495/4885FFAR1 2212/4885FFAR4 3672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.